MBB 196 Undergraduate Seminar: Breaking the Resistance – Dual FGFR and AKT Inhibition in NSCLC

Dual Inhibition of EGFR and Akt Pathways: A Synergistic Strategy to Overcome Therapeutic Resistance in Non-Small Cell Lung Cancer

Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remains a major therapeutic challenge in treating non-small cell lung cancer (NSCLC). Recent studies have identified the concurrent activation of the FGFR1-Akt signaling axis as one of the critical mechanisms underlying this resistance.

This seminar will discuss the rationale and preclinical evidence supporting the combined inhibition of EGFR and Akt pathways as a targeted strategy to restore drug sensitivity in FGFR1-overexpressing NSCLC models. The dual inhibition approach has demonstrated superior efficacy compared to monotherapies and offers a promising direction for the development of next-generation combination treatments in precision oncology.

Join us on Friday, May 16 for the MBB 196 Undergraduate Seminar, to be held at the National Institute of Molecular Biology and Biotechnology (NIMBB), Room 105, at 1:00 PM. All are welcome to attend.